NCT07499531Not yet recruiting
The Effect of Pulse Field Ablation of Atrial Fibrillation Involving Posterior Wall Ablation on Atrial Mechancis Assessed by Cardiac Magnetic Resonance Imaging
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
Assessing the impact of a new atrial fibrillation (AF) catheter ablation energy on left atrial structure and function is of crucial importance. The goal of this clinical trial is to assess the effect of pulsed-field ablation of atrial fibrillation on left atrial structure.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- First submitted
- 24 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2026
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Atrial fibrillation
- NCT number
- NCT07499531
What you commit to
- Study type: Interventional
- Planned participants: 39
- From Apr 2026 to the primary completion date, Apr 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ablation in the left atrium
- Previous heart surgery
- Participation in another interventional study or being in the exclusion period at the end of a previous study.
Other illness
- Significant valvular heart disease defined as any moderate (grade 3) or severe (grade 4) mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or tricuspid stenosis
Lab values
- Contraindication to perform MRI or using the DOTAREM™ contrast product (pacemaker, defibrillator, foreign body or prosthesis, old generation heart valves, old generation ferromagnetic vascular surgical clips, percutaneous devices for endocranial aneurysms, neurosimulator, cochlear implants, automated injection device such as insulin pump, and more generally any non-removable electronic device, severe kidney disease with GFR \< 30 mL/min, documented hypersensitivity to gadoteric acid or to excipients, severe claustrophobia)
Other
- Only pulmonary vein isolation is scheduled
- Atrial fibrillation present at ECG during the pre-ablation (V1a) visit
- Contraindication to oral anticoagulation
- Intracardiac thrombus
- Patient on AME (state medical aid)
- Pregnant or breast-feeding female
- Patient protected by law (guardianship, tutelage measure, deprived of liberty)
Who the study is looking for
- Patient age ≥ 18
- Established diagnosis of persistent or paroxysmal atrial fibrillation with a I/IIa/IIb indication for catheter ablation (ESC 2020 guidelines)
- AF ablation procedure planned using pulsed-field ablation and including at least pulmonary vein isolation and posterior wall isolation
- Episode of AF documented by ECG within the last 12 months
- Patient able to give written informed consent
- If female of childbearing potential, have a negative serum pregnancy test and using effective contraception
- Be affiliated with a French social security system or entitled
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.